Ruthenium(II) Complexes Containing Anti-Inflammatory Drugs as Ligands: Synthesis, Characterization and<i>in vitro</i>Cytotoxicity Activities on Cancer Cell Lines

Lopes, J.; Damasceno, Jaqueline Lopes; Oliveira, Pollyanna Francielli de; Guedes, Adriana P. M.; Tavares, Denise Crispim; Deflon, Victor M.; Lopes, Norberto P.; Pivatto, Marcos; Batista, Alzir A.; Maia, Pedro Ivo da Silva; Poelhsitz, Gustavo Von

doi:10.5935/0103-5053.20150161

Cited by 11 publications

(13 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…) 62. The 13 C NMR spectra of these complexes show singlets at 190.3 and 189.5 ppm for Ru 1 and Ru 2 , respectively, attributed to the chelating bidentate carboxylates, which are consistent with chemical shifts reported in the literature for Ru complexes bearing chelating bidentate acetate ligands 63.…”

supporting

confidence: 87%

3D Ruthenium Nanoparticle Covalent Assemblies from Polymantane Ligands for Confined Catalysis

et al. 2020

View full text Add to dashboard Cite

The synthesis of metal nanoparticle (NP) assemblies stabilized by functional molecules is an important research topic in nanoscience, and the ability to control interparticle distances and positions in NP assemblies is one of the major challenges in designing and understanding functional nanostructures. Here, two series of functionalized adamantanes, bisadamantanes and diamantanes bearing carboxylic acid or amine functional groups have been used as building blocks to produce, via a straightforward method, networks of ruthenium NP. Both the nature of the ligand and the Ru/ligand ratio affect the interparticle distance in the assemblies. The use of 1,3-adamantanedicarboxylic acid allows the synthesis of 3D networks of 1.7-1.9 nm Ru NP presenting interparticle distance of 2.5-2.7 nm. The surface interaction between Ru NP and the ligands were investigated spectroscopically using a 13 C labeled ligand, as well as theoretically with Density Functional Theory (DFT) calculations. We found that Ru species formed during the NP assembly are able to partially decarbonylate carboxylic acid ligands at room temperature. Decarbonylation of a carboxylic acid at room temperature in the presence of dihydrogen usually occurs on catalysts at much higher temperature and pressure. This result reveals a very high reactivity of ruthenium species formed during network assembling. The Ru NP networks were found active catalysts for the selective hydrogenation of phenyl acetylene, reaching good selectivity towards styrene. Overall, we demonstrated that catalyst activity, selectivity, and NP network stability are significantly affected by Ru NP interparticle distance, and electronic ligand effects. As such, these materials constitute a unique set that should allow a better understanding of the complex surface chemistry in carbonsupported metal catalysts.

show abstract

supporting

confidence: 87%

3D Ruthenium Nanoparticle Covalent Assemblies from Polymantane Ligands for Confined Catalysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Furthermore, several studies suggest that COX-2 inhibitors such as NSAIDs might not only play a role in the treatment of breast cancer, but also in its prevention [80]. For instance, the in vitro cytotoxicity of two cationic ruthenium(II) dppm (diphenylphosphinomethane) complexes (12), respectively bearing diclofenac (Ru-Dicl) and ibuprofen (Ru-Ibp) ( Figure 3) in MCF7 breast cancer cells, was reported by Von Poelhsitz et al (2015) and compared with that of a ruthenium complex control (with no bioactive ligand), cis-[RuCl 2 (dppm) 2 ], and cisplatin [81]. Both ruthenium complexes displayed a higher cytotoxicity (IC 50 = 47 ± 6 µM for Ru-Dicl, MCF7; IC 50 = 9 ± 3 µM for Ru-Ibp, MCF7) than that of the ruthenium complex control (IC 50 = 191 ± 13 µM, MCF7), highlighting the importance of the NSAID ligand on the anticancer activity of the compounds.…”

Section: Other Ruthenium Complexes For the Treatment Of Hormone Recepmentioning

confidence: 80%

“…Both ruthenium complexes displayed a higher cytotoxicity (IC 50 = 47 ± 6 µM for Ru-Dicl, MCF7; IC 50 = 9 ± 3 µM for Ru-Ibp, MCF7) than that of the ruthenium complex control (IC 50 = 191 ± 13 µM, MCF7), highlighting the importance of the NSAID ligand on the anticancer activity of the compounds. Moreover, the IC 50 value of Ru-Ibp was found to be significantly lower than that of cisplatin (IC 50 = 34 ± 4 µM, MCF7) [81]. It is worth mentioning that the potential COX inhibition activity of the compounds discussed above was not studied.…”

Section: Other Ruthenium Complexes For the Treatment Of Hormone Recepmentioning

confidence: 91%

Rationally Designed Ruthenium Complexes for Breast Cancer Therapy

Golbaghi

Castonguay

2020

Molecules

View full text Add to dashboard Cite

Since the discovery of the anticancer potential of ruthenium-based complexes, several species were reported as promising candidates for the treatment of breast cancer, which accounts for the greatest number of new cases in women every year worldwide. Among these ruthenium complexes, species containing bioactive ligand(s) have attracted increasing attention due to their potential multitargeting properties, leading to anticancer drug candidates with a broader range of cellular targets/modes of action. This review of the literature aims at providing an overview of the rationally designed ruthenium-based complexes that have been reported to date for which ligands were carefully selected for the treatment of hormone receptor positive breast cancers (estrogen receptor (ER+) or progesterone receptor (PR+)). In addition, this brief survey highlights some of the most successful examples of ruthenium complexes reported for the treatment of triple negative breast cancer (TNBC), a highly aggressive type of cancer, regardless of if their ligands are known to have the ability to achieve a specific biological function.

show abstract

“…It is widely known that phenolic acids and flavonoids, such as caffeic acid derived from hydroxycinnamic acids found in the soybean meal aqueous extract display antitumoral activity [30]. Cell viability decreases could be caused by the structural and functional damages in the assessed cell lineage [46]. Additional studies are required to determine what types of and the extension of the damage that the soybean meal aqueous extract caused to tumoral and healthy mouse BM and L929 cells.…”

Section: Discussionmentioning

confidence: 99%

Recovery of Antimicrobials and Bioaccessible Isoflavones and Phenolics from Soybean (Glycine max) Meal by Aqueous Extraction

et al. 2018

View full text Add to dashboard Cite

Soybeans display strategic potential in food security as a source of protein and functional bioactives for human consumption. Polyphenols and other bioactive compounds can be recovered after an aqueous extraction from soybean meal, a byproduct of soy oil refining. The objective of the present study was to compile and quantify compounds from soybean oil refinery by-products, providing information about valuable bioactive phytochemicals, their bioaccessibility and potential bioactivities. Genistin, daidzin, glycitin and malonylgenistin were the predominant isoflavones, and the overall bioaccessibility of their glycosidic forms was of nearly 75%. Sixteen phenolics were identified and caffeic acid, 5-caffeoylquinic chlorogenic acid and hesperidin were the most predominant. Approximately 30% of gallic acid, syringic acid, vanillic acid and myricetin were released and the antioxidant capacity of aqueous extract was enhanced after simulated in vitro gastro intestinal digestion. The ability of aqueous soybean meal extract to inhibit lipid peroxidation was higher than natural and synthetic food antioxidants. Antimicrobial activity against several foodborne pathogens and antitumoral activity towards human glioblastoma cell line were also observed, but the aqueous extract showed no cytotoxicity to healthy murine cells. Compounds derived from the aqueous soybean meal extract have the potential to be used as health promoting agents.

show abstract

Ruthenium(II) Complexes Containing Anti-Inflammatory Drugs as Ligands: Synthesis, Characterization andin vitroCytotoxicity Activities on Cancer Cell Lines

Cited by 11 publications

References 1 publication

3D Ruthenium Nanoparticle Covalent Assemblies from Polymantane Ligands for Confined Catalysis

3D Ruthenium Nanoparticle Covalent Assemblies from Polymantane Ligands for Confined Catalysis

Rationally Designed Ruthenium Complexes for Breast Cancer Therapy

Recovery of Antimicrobials and Bioaccessible Isoflavones and Phenolics from Soybean (Glycine max) Meal by Aqueous Extraction

Contact Info

Product

Resources

About